Narhex Life Sciences has made significant progress towards its ultimate goal of building a company based on the clinical and commercial success of therapeutic and diagnostic products which are used to manage patients with HIV infection.

To progress its clinical trials and expand its sales force for its HIV/AIDS Diagnostic kits throughout Asia, Narhex is raising an additional $2.8M through a 1 for 5 rights issue to existing shareholders and placement at 5 cents. This offer represents an attractive discount to the 6.2 cents the shares closed at on 10 April 2007.
CLICK HERE for more information and to download a copy of the appropriate prospectus.